# Corning Incorporated – Consensus ‘buy’ rating and 20.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/corning-incorporated-consensus-buy-rating-and-20.7-upside-potential/4121127873
- Published: 2023-09-20T14:34:09+01:00
- Author: Charlotte Edwards

**Corning Incorporated** with ticker code (GLW) have now 10 analysts in total covering
the stock. The consensus rating is pointing to ‘buy’. The range between the high
target price and low target price is between 43 and 33 suggesting an average Analsyt
target price of $38.10. Given that the stocks previous close was at $31.57 this 
is indicating there is a potential upside of 20.7%. Also worth taking note is the
50 day moving average now sits at $32.80 and the 200 moving average now moves to
$33.48. The company has a market capitalization of 27.19B. The current share price
for the company is: 31.88 USD

 The potential market cap would be $32,817,731,849 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 43.08, revenue per share of 15.77
and a 2.99% return on assets.

Corning Incorporated is a materials science technology and innovation company. The
Company operates through five segments: Optical Communications, Display Technologies,
Specialty Materials, Environmental Technologies and Life Sciences. The Optical Communications
segment manufactures carrier network and enterprise network components for the telecommunications
industry. The Display Technologies segment manufactures glass substrates for flat
panel liquid crystal displays and other high-performance display panels. Its Specialty
Materials segment is engaged in manufacturing products that provide material formulations
for glass, glass ceramics and fluoride crystals to meet demand for customer needs.
Its Environmental Technologies segment manufactures ceramic substrates and filters
for emission control systems. Its Life Sciences segment manufactures glass and plastic
labware, equipment, media, serum and reagents enabling workflow solutions for drug
discovery and bioproduction.

Share on: